THE MCMANUS GROUP

Lobbying registrant · 286096

52 filings on record; a reported $2,640,000 in total across them. Honesty note: each amount is the registrant's reported lobbying income/spend for that quarter (a lump sum required by the Lobbying Disclosure Act, or LDA — the law governing public lobbying reports), so this total is a gross sum of quarterly figures. The filings do disclose which bills were lobbied on (below), but never how much of the money went to any one bill, and never whether the filer supported or opposed it.

Clients

Filings

ClientPeriodReported quarterly amountFiling type
ZIMMER BIOMET Q2 2026 $50,000 Q2
WEX HEALTH Q2 2026 $50,000 Q2
VIVEX BIOLOGICS Q2 2026 $50,000 Q2
VIALASE INC. Q2 2026 $50,000 Q2
VENTURE MEDICAL Q2 2026 $30,000 Q2
ROCHE DIAGNOSTICS Q2 2026 $40,000 Q2
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA Q2 2026 $60,000 Q2
OWLET Q2 2026 $30,000 Q2
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) Q2 2026 $60,000 Q2
MEDICAL DEVICE MANUFACTURERS ASSOCIATION Q2 2026 $30,000 Q2
LARGE UROLOGY GROUP PRACTICE ASSOCIATION Q2 2026 $90,000 Q2
INFUSION PROVIDERS ALLIANCE Q2 2026 $90,000 Q2
GRAIL, INC. Q2 2026 $50,000 Q2
GILEAD SCIENCES, INC. Q2 2026 $60,000 Q2
GENENTECH Q2 2026 $50,000 Q2
FULCRUM THERAPEUTICS Q2 2026 $60,000 2T
DENDREON PHARMACEUTICALS LLC Q2 2026 $30,000 Q2
BRISTOL-MYERS SQUIBB Q2 2026 $80,000 Q2
BIOWOUND SOLUTIONS Q2 2026 $50,000 Q2
AMBULATORY SURGERY CENTER ASSOCIATION Q2 2026 $60,000 Q2
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION Q2 2026 $40,000 Q2
ARDELYX Q2 2026 $60,000 Q2
AMGEN Q2 2026 $60,000 Q2
ACESSO BIOLOGICS Q2 2026 $60,000 Q2
VENTURE MEDICAL Q1 2026 $20,000 Q1
VIALASE INC. Q1 2026 $50,000 Q1
OWLET Q1 2026 $30,000 Q1
ARDELYX Q1 2026 $60,000 Q1
ZIMMER BIOMET Q1 2026 $50,000 Q1
ACESSO BIOLOGICS Q1 2026 $60,000 Q1
BIOWOUND SOLUTIONS Q1 2026 $50,000 Q1
VIVEX BIOLOGICS Q1 2026 $50,000 Q1
WEX HEALTH Q1 2026 $50,000 Q1
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) Q1 2026 $60,000 Q1
MEDICAL DEVICE MANUFACTURERS ASSOCIATION Q1 2026 $30,000 Q1
LARGE UROLOGY GROUP PRACTICE ASSOCIATION Q1 2026 $90,000 Q1
GRAIL, INC. Q1 2026 $50,000 Q1
GILEAD SCIENCES, INC. Q1 2026 $60,000 Q1
GENENTECH Q1 2026 $50,000 Q1
DENDREON PHARMACEUTICALS LLC Q1 2026 $30,000 Q1
FULCRUM THERAPEUTICS Q1 2026 $50,000 Q1
ROCHE DIAGNOSTICS Q1 2026 $40,000 Q1
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA Q1 2026 $60,000 Q1
INFUSION PROVIDERS ALLIANCE Q1 2026 $90,000 Q1
AMBULATORY SURGERY CENTER ASSOCIATION Q1 2026 $60,000 Q1
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION Q1 2026 $40,000 Q1
AMGEN Q1 2026 $60,000 Q1
MEDICARE ALLIANCE FOR BENEFICIARY ACCESS (MABA) Q1 2026 $40,000 1T
ROYAL BIOLOGICS Q1 2026 $20,000 1T
SIGHT SCIENCES Q1 2026 $20,000 1T
BRISTOL-MYERS SQUIBB Q1 2026 $80,000 Q1
VENTURE MEDICAL Q1 2026 not reported RR

Source: Senate LDA filings.

Bills lobbied on

Bills named in this registrant's filings. A titled link means the bill is in our corpus; a bare canonical reference means it is not.

Bill references are free-text extractions from LDA specific_issues; they show a bill was named in a quarter, not money spent on it.

Lobbying ≠ campaign money. These LDA lobbying figures are a separate, unbridged channel from FEC campaign contributions; this platform does not yet link a lobbying registrant to any FEC committee. See the methodology glossary.